title: Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
abstract: BACKGROUND
  There is no information as to the extent by which Spanish gastroenterologists adhere to Crohn's disease (CD) management guidelines. The objective of this study was to evaluate the degree of adherence of Spanish gastroenterologists to the European Crohn's and Colitis Organisation (ECCO) guidelines and to determine whether differences in adherence exist between gastroenterologists specialized in inflammatory bowel diseases (GSIBDs) and general gastroenterologists (GGs).
  
  
  METHODS
  This was a prospective, nation-wide, questionnaire-based survey covering aspects related to diagnosis, treatment, follow-up, and safety considered by the physicians in their daily management of CD, as well as demographic traits seen in clinical practice.
  
  
  RESULTS
  The overall degree of adherence to guidelines by both GSIBDs and GGs was high. However, the use of imaging techniques in diagnosis, follow-up, and in relapsed patients differed between the two groups. In the diagnosis of perianal disease, GSIBDs used magnetic resonance and surgical exploration under anesthesia more frequently than GGs. In terms of therapeutic choices, the adherence to guidelines was good in both groups. However, GSIBDs showed significantly higher adherence in some areas: thiopurines were used less in refractory cases and methotrexate was used more commonly in corticoid-dependent, azathioprine-intolerant patients, and in patients under biological treatment. Request for infection studies and vaccinations at diagnosis or prior to treatment was more common among GSIBDs.
  
  
  CONCLUSIONS
  Guideline adherence among Spanish gastroenterologists is high. However, there are significant differences between IBD-specialized (more adherent in general) and non-specialized gastroenterologists.
authors.affiliation: Departamento de Gastroenterología, Hospital de Manises, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Hinojosa
authors.forename: J P
authors.initials: JP
authors.lastname: Gisbert
authors.forename: F
authors.initials: F
authors.lastname: Gomollón
authors.forename: A
authors.initials: A
authors.lastname: López San Román
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy*; D005762:Gastroenterology / Q000592:standards* / Q000706:statistics & numerical data*; D005938:Glucocorticoids / Q000627:therapeutic use; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006509:Hepatitis B / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D007251:Influenza, Human / Q000517:prevention & control; D008727:Methotrexate / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D013030:Spain; D013038:Specialization / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires; D014611:Vaccination
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069285:Infliximab; D000068879:Adalimumab; D001379:Azathioprine; D008727:Methotrexate